pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·5h ago·1 min read
save

J&J proposes $5.5B talc settlement

After more than a decade and three failed bankruptcy attempts, an end to Johnson & Johnson’s talc saga may finally be in sight. The company has proposed a $5.5 billion settlement ...

Jul 28, 2026·read at Endpoints ↗Neutral

July 28, 2026 02:33 PM EDT PharmaLaw J&J pro­pos­es $5.5B talc set­tle­ment Nicole DeFeudis Senior Reporter Af­ter more than a decade and three failed bank­rupt­cy at­tempts, an end to John­son & John­son’s talc saga may fi­nal­ly be in sight. The com­pa­ny … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
76 words · retrieved 4h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 4h agoFDA reminds investors about the risks of advisory panelsEndpoints
  • 5h agoFDA offers updated guidance for generics of weight loss blockbustersEndpoints
  • 8h agoOak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3Endpoints
  • 8h agoFDA staff say Replimune's melanoma trial failed to prove RP1 worksEndpoints
  • 9h agoThe future of gray-market peptidesEndpoints